IRP Investigators Begin Hundreds of New Coronavirus-Related Studies
Monday, June 15, 2020
Within just a few months after COVID-19 began spreading in the United States, IRP researchers had already made numerous important contributions to the fight against the deadly virus. Scientific knowledge about the disease continues to expand at a unprecedented pace, and the IRP will continue to play a major role in this effort over the coming months and years. In fact, nearly 300 new intramural research projects related to the novel coronavirus are currently starting up or have already begun.
Four Questions with Dr. John Mascola
Friday, November 29, 2019
The disease known as human immunodeficiency virus, or HIV, attacks and destroys cells vital to the immune system. This leaves the millions of people living with HIV less able to fight other infections and can lead to an extremely severe form of immune system deficiency called acquired immunodeficiency syndrome (AIDS), which was responsible for nearly 770,000 deaths in 2018 alone. As of 2019, there are approximately 37.9 million people around the world living with HIV/AIDS.
Although HIV/AIDS has been recognized as a serious public health crisis, finding effective treatments, or a vaccine to prevent infection in the first place, is not a simple task. The HIV virus has many different types and strains — similar to the flu — which makes developing vaccines and treatments extremely challenging, as the virus is constantly changing. At the NIH, there are a number of ongoing collaborative research projects aimed at providing new options for those diagnosed with HIV/AIDS and those at risk for contracting the virus in the future.
Six Questions With Dr. Matthew Memoli
Thursday, August 22, 2019
We all know flu season as the time of year where people are loading up on hand sanitizer and heading to the doctor for their flu shot. However, many underestimate the severity of the flu. During a typical flu season, five to twenty percent of Americans fall ill, leading to more than 200,000 hospitalizations and 36,000 deaths. Because of this serious threat to the public, the IRP has a long track record of researching vaccines, antivirals, diagnostics, and other resources in an effort to prevent individuals from catching the flu and improve care for those who do.
A Conversation with Dr. Paolo Lusso
Thursday, June 27, 2019
First discovered in 1981, human immunodeficiency virus, or HIV, caused one of the most deadly and persistent epidemics in history. HIV destroys CD4+ T cells, a type of white blood cell essential for fighting infection. In doing so, HIV destroys the body’s ability to fight off disease, which often leads to life-threatening consequences.
Today, medications have allowed people living with HIV to lead healthier lives. However, HIV still remains a major public health concern and continues to be studied by researchers within the IRP and beyond.
IRP research has produced findings essential to the development of current HIV treatments and tools for diagnosis. However, there is still a lot left to learn. One recent IRP contribution to HIV research was a 2017 study led by IRP senior investigator Paolo Lusso, M.D., Ph.D., which suggests that treatments targeting a protein called integrin α4β7 could potentially become an addition to current treatment options for those with HIV, or provide new measures to prevent infection.
Tuesday, September 4, 2018
With summer winding down, it's about time we took another dive into some NIH history! These new additions to the NIH Stetten Museum collection feature some of the most prominent investigators ever to walk the NIH campus, including a Nobel prize winner and a scientist who made important discoveries about how electricity travels between neurons.
Tuesday, May 22, 2018
NIH history is rife with legends, scientists who have made remarkable discoveries and incalculable contributions to the health and longevity of humankind. There are living legends; just peruse the “Honors” page on the IRP website to see what I mean. And there are greats who are gone but certainly not forgotten.
Tuesday, November 15, 2016
The surprising results of an animal study are raising hopes for a far simpler treatment regimen for people infected with the AIDS-causing human immunodeficiency virus (HIV). Currently, HIV-infected individuals can live a near normal life span if, every day, they take a complex combination of drugs called antiretroviral therapy (ART). The bad news is if they stop ART, the small amounts of HIV that still lurk in their bodies can bounce back and infect key immune cells, called CD4 T cells, resulting in life-threatening suppression of their immune systems.